Quantcast
Last updated on April 20, 2014 at 21:20 EDT

Latest Cardiome Pharma Corp. Stories

2014-03-28 08:26:22

NASDAQ: CRME TSX: COM VANCOUVER, March 28, 2014 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that Cardiome International A.G., a subsidiary of Cardiome Pharma Corp., has entered into an agreement with VIANEX, S.A., headquartered in Erythrea, Greece, for the commercialization and distribution of BRINAVESS(TM) (vernakalant IV) in Greece. Under the terms of the agreement, VIANEX has agreed to specific annual commercial goals for BRINAVESS. "We...

2014-03-27 08:33:49

Cardiome to conduct conference call and webcast today, March 27, at 8:00 a.m. Eastern (5:00 a.m. Pacific) NASDAQ: CRME TSX: COM VANCOUVER, March 27, 2014 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today reported financial results for the fourth quarter and year ended December 31, 2013. Amounts, unless specified otherwise, are expressed in U.S. dollars and in accordance with generally accepted accounting principles used in the United States (U.S. GAAP)....

2014-03-20 08:29:29

NASDAQ: CRME TSX: COM VANCOUVER, March 20, 2014 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that it will report financial results for the fourth quarter and fiscal year ended December 31, 2013 on the morning of Thursday, March 27, 2014. Cardiome will hold a conference call and webcast at 8:00 a.m. Eastern (5:00 a.m. Pacific) on that day to discuss the results. To access the conference call, please dial 416-764-8688 or 888-390-0546 and use...

2014-03-19 08:28:39

NASDAQ: CRME TSX: COM VANCOUVER, March 19, 2014 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that the company has entered into a distribution agreement with Logista Pharma S.A., headquartered in Madrid, Spain, to distribute BRINAVESS(TM) (vernakalant IV) within the Spanish market. "We are pleased to have entered into this agreement with Logista Pharma to distribute BRINAVESS to our Spanish customers," said Karim Lalji, Cardiome's Chief...

2014-02-20 08:30:04

VANCOUVER, Feb. 20, 2014 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) ("Cardiome") and CarCor Investment Holdings LLC ("CarCor"), the shareholder from which Cardiome purchased Correvio LLC, are pleased to announce that they have entered into an agreement with a group of underwriters (the "Underwriters") for the sale, on a bought deal basis, of 1,500,000 common shares from Cardiome for gross proceeds of C$15 million (the "Primary Offering") and 1,500,000 common...

2014-02-19 08:33:56

NASDAQ: CRME TSX: COM VANCOUVER, Feb. 19, 2014 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that pursuant to its agreement of July 2013, the company has begun shipping BRINAVESS(TM) (vernakalant intravenous) to AOP Orphan Pharmaceuticals AG, headquartered in Vienna, Austria, now making the product available to physicians and patients in Switzerland, the Czech Republic, Poland, Slovenia, Slovakia, Hungary, Latvia and Romania. AOP Orphan will...

2014-02-18 08:30:46

NASDAQ: CRME TSX: COM VANCOUVER, Feb. 18, 2014 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME) (TSX: COM) today announced that its subsidiary, Correvio GmbH, has entered into an agreement with Nomeco A/S, headquartered in Copenhagen, Denmark, to distribute BRINAVESS(TM) (vernakalant IV) to customers in the Danish market. "We are pleased to have entered into this distribution agreement with Nomeco," said Karim Lalji, Cardiome's Chief Commercial Officer. "In addition to...

2014-02-18 08:30:44

NASDAQ: CRME TSX: COM VANCOUVER, Feb. 18, 2014 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that it has entered into an At Market Sales Issuance Agreement with MLV & Co. LLC (MLV) pursuant to which the company may from time to time sell, through at-the-market (ATM) offerings and MLV as agent, such common shares as would have an aggregate offer price of up to U.S.$30,000,000. Cardiome has also filed a prospectus supplement with securities...

2014-02-13 08:30:36

NASDAQ: CRME TSX: COM VANCOUVER, Feb. 13, 2014 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME) (TSX: COM) today announced that a poster titled "Medical conversion with Vernakalant on postoperative cardio-surgical patients" by Thöne, M. et al., from the Department of Cardiovascular Surgery at the Heinrich-Heine-University Düsseldorf located in Düsseldorf, Germany, was presented at the 43(rd) Annual Meeting of the Germany Society for Thoracic and Cardiovascular Surgery...

2014-02-11 08:31:47

NASDAQ: CRME TSX: COM VANCOUVER, Feb. 11, 2014 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that its subsidiary, Correvio GmbH, has entered into an agreement with Tamro AB, headquartered in Gothenburg, Sweden, to distribute BRINAVESS® (vernakalant IV) to customers in the Swedish market. "We are delighted to have entered into this distribution agreement with Tamro, a leader in pharmaceutical distribution in Sweden," said Karim Lalji,...